T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
THRX
1351
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $7.66M | ﹤0.01% |
1,385,283
-51,333
| -4% | -$424K |
|
1352
Matsons
MATX
$6.41B
| $7.66M | ﹤0.01% |
105,087
-892,081
| -89% | -$76.7M |
|
|
ZEN
1353
DELISTED
ZENDESK INC
ZEN
| $7.56M | ﹤0.01% |
102,102
+3,626
| +4% | +$358K |
|
|
HZN
1354
DELISTED
Horizon Global Corporation
HZN
| $7.53M | ﹤0.01% |
4,616,294
| – | – |
|
|
USX
1355
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $7.5M | ﹤0.01% |
2,800,381
+1,129,350
| +68% | +$3.52M |
|
1356
Trinity Capital Inc.
TRIN
$1.73B
| $7.47M | ﹤0.01% |
515,937
-472
| -0.1% | -$7.73K |
|
1357
Douglas Dynamics
PLOW
$981M
| $7.46M | ﹤0.01% |
259,440
-45,476
| -15% | -$1.41M |
|
1358
Carlisle Companies
CSL
$15.2B
| $7.44M | ﹤0.01% |
31,190
+867
| +3% | +$216K |
|
1359
Barings BDC
BBDC
$966M
| $7.38M | ﹤0.01% |
792,351
-809
| -0.1% | -$8.21K |
|
1360
DaVita
DVA
$11.6B
| $7.38M | ﹤0.01% |
92,239
-96,378
| -51% | -$9.75M |
|
1361
Ovintiv
OVV
$17.5B
| $7.29M | ﹤0.01% |
165,078
+19,727
| +14% | +$1.02M |
|
1362
Orchestra BioMed
OBIO
$266M
| $7.24M | ﹤0.01% |
727,202
-66,876
| -8% | -$665K |
|
1363
Armstrong World Industries
AWI
$7.75B
| $7.17M | ﹤0.01% |
95,646
-70
| -0.1% | -$5.92K |
|
1364
Chewy
CHWY
$9.15B
| $7.11M | ﹤0.01% |
204,659
-18,424
| -8% | -$591K |
|
1365
Applovin
APP
$105B
| $7.08M | ﹤0.01% |
205,620
-26,299
| -11% | -$1.06M |
|
|
BCYC
1366
Bicycle Therapeutics
BCYC
$284M
| $7.07M | ﹤0.01% |
421,261
-264,615
| -39% | -$5.58M |
|
1367
GitLab
GTLB
$7.32B
| $7.05M | ﹤0.01% |
132,759
-57,714
| -30% | -$2.68M |
|
1368
Envista
NVST
$4.61B
| $7.04M | ﹤0.01% |
182,617
+1,216
| +0.7% | +$51.1K |
|
1369
SOPHiA GENETICS
SOPH
$644M
| $7.03M | ﹤0.01% |
1,941,282
-378,458
| -16% | -$1.92M |
|
1370
Senti Biosciences Holdings
SNTI
$12M
| $7M | ﹤0.01% |
358,959
+348,892
| +3,466% | +$28M |
|
1371
Consensus Cloud Solutions
CCSI
$695M
| $6.88M | ﹤0.01% |
157,596
+79
| +0.1% | +$3.93K |
|
1372
Robinhood
HOOD
$89.3B
| $6.82M | ﹤0.01% |
829,556
+559,694
| +207% | +$5.45M |
|
|
EB
1373
DELISTED
Eventbrite
EB
| $6.78M | ﹤0.01% |
660,547
-28,179
| -4% | -$336K |
|
|
BLSA
1374
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $6.73M | ﹤0.01% |
680,121
-61,249
| -8% | -$606K |
|
|
INFA
1375
DELISTED
Informatica
INFA
| $6.71M | ﹤0.01% |
323,176
-8,412
| -3% | -$167K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.